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Abstract
Background & Aims—Cigarette smoking has been implicated in the etiology of esophageal
adenocarcinoma, but it is not clear if smoking is a risk factor for Barrett’s esophagus (BE). We
investigated whether tobacco smoking and other factors increase risk for BE.
Methods—We analyzed data from 5 case-control studies included in the international Barrett’s
and Esophageal Adenocarcinoma Consortium. We compared data from subjects with BE (n=1059)
with those from subjects with gastroesophageal reflux disease (GERD controls, n=1332) and
population-based controls (n=1143), using multivariable logistic regression models to test
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associations with cigarette smoking. We also tested whether cigarette smoking has synergistic
effects with other exposures, which might further increase risk for BE.
Results—Subjects with BE were significantly more likely to have ever-smoked cigarettes than
the population-based controls (odds ratio [OR]=1.67; 95% confidence interval [CI], 1.04–2.67) or
GERD controls (OR=1.61; 95% CI, 1.33–1.96). Increasing pack-years of smoking increased the
risk for BE. There was evidence for a synergy between ever-smoking and heartburn or
regurgitation; the attributable proportion of disease among individuals who ever smoked and had
heartburn or regurgitation was estimated to be 0.39 (0.25–0.52).
Conclusions—Cigarette smoking is a risk factor for BE. The association strengthened with
increased exposure to smoking until ~ 20 pack-years, when it began to plateau. Smoking has
synergistic effects with heartburn or regurgitation, indicating that there are various pathways by
which tobacco smoking might contribute to the development of BE.
Keywords
BEACON; esophageal cancer; population study; tobacco
Introduction
Barrett’s esophagus is a columnar metaplasia of the distal esophagus associated with a 10- to
55-fold increased risk of esophageal adenocarcinoma 1–7. Barrett’s esophagus 8–11 and
esophageal adenocarcinoma 12–14 have been increasing in incidence, particularly in
developed countries with predominantly Caucasian populations. For example, in the United
States esophageal adenocarcinoma in whites has increased from 0.4 to more than 3 per
100,000 person-years during the last 35 years—a 650% increase 12, 15. This increasing
incidence is not solely due to changes in diagnostic practice, and has been attributed to
temporal changes in exposure to risk factors 16.
The known risk factors for Barrett’s esophagus and esophageal adenocarcinoma are few and
include gastroesophageal reflux 17, 18 and increasing body mass index (BMI) 19–21.
Cigarette smoking has also been implicated in the etiology of esophageal
adenocarcinoma 22, but whether this is because smoking is a risk factor for early events in
the carcinogenic pathway (i.e. Barrett’s esophagus) or for later events, such as the
transformation of Barrett’s esophagus to cancer, is unclear given the conflicting findings of
previous studies of Barrett’s esophagus risk factors, with some studies demonstrating a
positive association between Barrett’s esophagus and cigarette smoking 18, 23–27 and others
not 28–32.
The inability to ascertain what, if any, relationship exists between Barrett’s esophagus and
smoking has been due, in part, to imprecision rendered by limited numbers of subjects
available for analysis in individual studies. This limitation has also reduced the ability to
discern interactions between exposures; if tobacco smoking does increase risk of Barrett’s
esophagus it could do so primarily through genotoxic mechanisms or by promoting GERD.
Refining our understanding of the potential mechanism(s) of association is important with
regard to the efficacy of preventative actions.
To better understand the relationship between Barrett’s esophagus and one of its few
potentially modifiable risk factors, we assessed whether cigarette smoking was associated
with Barrett’s esophagus, and the potential mechanism of association, by pooling,
harmonizing, and analyzing individual patient data from five case-control studies in the
international Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON,
http://beacon.tlvnet.net/).
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The BEACON consortium was formed in 2005 with support from the U.S. National Cancer
Institute. It is composed of investigators from around the world and brings together
population-based case-control and cohort studies of esophageal adenocarcinoma and
Barrett’s esophagus. The primary objectives of BEACON are to facilitate well-powered,
combined investigations of risk factors in relation to these diseases, as well as helping the
development of new studies of etiology, prevention and survival.
The five Barrett’s esophagus case-control studies included in this BEACON analysis, with
abbreviated names shown in italics, were: FINBAR (Factors INfluencing the Barrett’s/
Adenocarcinoma Relationship) study, based in Ireland 33; Epidemiology and Incidence of
Barrett’s Esophagus study nested within Kaiser Permanente Northern California (KPNC),
USA 34; Study of Reflux Disease, based in western Washington State, USA 35; Study of
Digestive Health, based in Brisbane, Australia 26; and Epidemiologic Case-Control Study of
Barrett’s Esophagus based at The University of North Carolina at Chapel Hill (UNC-Chapel
Hill), USA. For comparison with Barrett’s esophagus cases, two control groups were
available: gastroesophageal reflux disease (GERD) and population-based. There are
advantages for each of these comparison groups. GERD controls represent the population
undergoing endoscopy from which Barrett’s esophagus cases are diagnosed. Therefore,
comparisons between these two groups are less affected by potential ascertainment bias than
comparisons between Barrett’s esophagus cases and population-based controls, insofar as it
inherently controls for known and unknown potentially confounding factors associated with
being referred for and undergoing an endoscopic procedure. In addition, since most cases are
identified in the course of investigating gastroesophageal reflux, the use of GERD controls,
to some degree, inherently adjusts for the presence, although not severity, of symptomatic
gastroesophageal reflux. The major advantage of the population-based control group is that
it enables the assessment of gastroesophageal reflux as both an effect-measure modifier and
independent risk factor, while also being representative of the local population from which
the Barrett’s esophagus cases are referred and diagnosed. Studies which have conducted
endoscopy on random samples of the general population provide more in-depth information
on the relative advantages and disadvantages of each of these two control groups 36, 37. All
five studies contributed individual patient data to the GERD control group and four of the
studies contributed individual patient data to the population-based control group. Study-
specific definitions of the case and control groups are detailed in Table 1.
In total, the five studies provided 1,320 cases of Barrett’s esophagus, 1,659 GERD controls,
and 1,434 population-based controls. For this analysis, and if a study provided such data, we
excluded individuals who had ever-smoked pipe tobacco or cigars (156 Barrett’s esophagus
cases, 132 GERD controls, 153 population-based controls), because comparing cigarette
smokers with those who do not use other forms of tobacco provides a more accurate
estimate of the effect of cigarette smoking. Ever-smoking of pipe tobacco or cigars was
defined as meeting a study-specific low threshold exposure (a period of ≥6 months or ≥20
times over the life-course). Due to the relatively small number of non-white Barrett’s
esophagus cases remaining (17 black, 31 Hispanic, 39 other, 18 missing), we restricted our
analysis to white study participants. After exclusions, there remained 1,059 Barrett’s
esophagus cases, 1,332 GERD controls, and 1,143 population-based controls for analysis.
Data acquisition and data pooling for each study were approved by the Institutional Review
Board or Research Ethics Committee of the institute(s) sponsoring the study.
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The primary exposure variables were cigarette smoking status (ever vs. never) and total
cigarette smoking exposure (pack-years; 0, <15, 15–29, 30–44, ≥45). Additional exposure
variables included duration of cigarette smoking (<30 years, ≥30 years), cigarette smoking
intensity (<1, 1, and >1 packs/day), age of cigarette smoking initiation (<17, ≥17 years), and
duration of cigarette smoking cessation (<20 years, ≥20 years). Cigarette smoking intensity
and cigarette smoking duration in the UNC-Chapel Hill study were ascertained in categories
and were thus recoded to the median of the categories using the distributions of the other
four studies combined. Ever-cigarette smoking was defined as either low threshold
exposures (≥100 cigarettes, >=20 packs of cigarettes, 1 cigarette a day for six months of
longer) or by asking whether the patient had ever-smoked. Covariates assessed for inclusion
in regression models included: age; sex; BMI (weight divided by square of height [kg/m2]);
education; alcohol; fat, and transfat consumption; calories per day; meat, vegetable, and fruit
servings per day; fiber consumption; heartburn, and regurgitation (population-based control
models only); esophagitis; Helicobacter pylori seropositivity; hiatal hernia; and medication
use (non-steroidal anti-inflammatory drugs [NSAIDs], antacids, proton pump inhibitors
[PPIs], H2-receptor antagonists [H2RAs]). A covariate was included in the fully adjusted
models if it altered an estimate by >10% or it was considered a known confounder (age, sex,
BMI, and education).
Statistical analysis
We used a two-step analytic approach. First, study-specific odds ratios (ORs) and 95%
confidence intervals (CIs) for an exposure-outcome relationship were estimated from
multivariable logistic regression models. Second, the study-specific ORs were combined
using fixed-effects and random-effects meta-analytic models to generate summary ORs;
both approaches gave similar estimates of association, thus we present only the random-
effects models herein as such models are usually more conservative 38. A study was
excluded from the second-step of a specific variable’s analysis if the logistic regression
model failed due to instability. The I2 value and its 95% uncertainty interval were used to
estimate the percentage of total variation across studies due to heterogeneity 39. An I2
statistic of 0% indicates no observed heterogeneity that cannot be attributed to chance,
whereas larger values indicate increasing heterogeneity.
Exposure variables were assessed in relation to the outcome of Barrett’s esophagus using
two comparison groups: GERD controls and population-based controls. Continuous
variables were categorized to allow for nonlinear effects, for ease of interpretation, and to
reduce the effect of any outliers; exceptions to this were the use of continuous variables for
trends, product-terms, and spline models. Minimally adjusted models included the covariates
age (years; <50, 50–59, 60–69, ≥70) and sex. Fully adjusted models also included BMI
(<18.5, 18.5–24, 25–29, 30–34, 35–39, ≥40 kg/m2) and education (categorical: school only,
tech/diploma, university; unavailable and so unadjusted for in UNC-Chapel Hill study).
These models were also stratified by sex, BMI, and heartburn or regurgitation (population-
based control comparisons only) to assess relationships (ORs) for effect-measure
modification, with p values estimated via random effects meta-analysis of study-specific
estimated effects of product-terms (e.g., ever-smoke x sex). Heartburn was generally
described to the patient as having ever experienced burning pain or discomfort behind the
breast bone while regurgitation was generally described as food or stomach fluid coming
back up into the mouth accompanied with a sour-taste; KPNC excluded symptoms within 1
year prior to diagnosis of Barrett’s esophagus and FINBAR 5 years. In addition, FINBAR
required symptoms to be frequent (more than 50 times per year/about once a week). Models
of the additional exposures (cigarette smoking duration, intensity, initiation, and cessation)
were also adjusted for total exposure (pack-years of cigarette smoking); because these
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variables contribute to total exposure, association testing without adjustment for total
exposure could be misleading 40, 41.
Spline models 42 were used to generate plots of the relationship between continuous pack-
years of cigarette smoking and risk of Barrett’s esophagus, compared with each control
group and adjusted for age, sex, BMI, and study using the pooled dataset of individual
patient data. Restricted cubic spline models allow for easy visualization of non-linear
relationships between an exposure and an outcome 43, 44—in this case, cigarette smoking
and Barrett’s esophagus. These models were plotted using a linear scale on the x-axis (pack-
years of cigarette smoking) and a logarithmic (base 10) scale on the y-axis (OR).
To determine whether cigarette smoking biologically interacts with other exposures in
relation to risk of Barrett’s esophagus, we tested for departure from additivity. Positive
departure from additivity implies that the number of cases attributable to two exposures in
combination is larger than the sum of the numbers of cases that would be caused by each
exposure separately. The covariates tested for biological interaction with ever-cigarette
smoking were BMI (<27.5, ≥ 27.5 kg/m2), heartburn and regurgitation (population-based
control comparisons only), alcohol, H. pylori, and NSAIDs. For each combination of
variables, we generated four exposure categories; using BMI as an example: A=never-
smoker, low BMI; B=smoker, low BMI; C=never-smoker, high BMI; D=smoker, high BMI.
These variables were modeled in the pooled dataset of individual patient data using logistic
regression adjusted for age, sex, BMI, education, and study. Assuming that the OR
approximates the relative risk, the output from these models was used to estimate three
interaction statistics: interaction contrast ratio (ICR), attributable proportion (AP), and
synergy index (S) 45, 46. When the ICR and AP ≠ 0, and S ≠ 1 there is evidence for
departure from additivity (biological interaction). ICR is the excess risk due to interaction
relative to the risk without either exposure. AP is the proportion of disease attributable to
interaction among individuals with both exposures. S is the ratio of the observed excess risk
in individuals exposed to both factors relative to the expected excess risk assuming that both
exposures are independent risk factors (i.e., under the assumption of no additive interaction).
Confidence intervals for these metrics were estimated using the delta method 45.
All analyses were performed using STATA software, version 11.1 (StataCorp LP, College
Station, TX). All statistical tests were two-sided and p values less than 0.05 were considered
to be statistically significant.
Results
Descriptors of cases and controls included in the analysis are shown in Table 2. The
population-based control distributions were more similar to the cases in terms of age and sex
than the GERD controls, and this is likely due to three of the four studies with population-
based controls having matched on these variables to the Barrett’s esophagus case group;
GERD controls were matched to the Barrett’s esophagus group on age and sex in only one
study (Table 1). However, in other respects, such as BMI and alcohol, GERD controls had
distributions more similar to the Barrett’s esophagus group, compared with the population-
based control group.
Table 3 shows the estimates of association between cigarette smoking variables and
Barrett’s esophagus, compared with both GERD controls and population-based controls.
Subjects with Barrett’s esophagus were significantly more likely to have ever-smoked
cigarettes than both the population controls (OR=1.67) and the GERD controls (OR=1.61),
although the GERD study-specific estimates appeared to be less heterogeneous (I2=11%,
95%UI:0–81%) than estimates from population-based control models (I2=82%, 95%UI:54–
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93%). Increasing pack-years of cigarette smoking was associated with an increasing OR for
Barrett’s esophagus compared with both control groups (Table 3, Figure 1), albeit the risk
relationship was not strictly linear in the categories used for assessment; the ORs for
Barrett’s esophagus were approximately 1.5 for both <15 and 15–29 pack-years of smoking
exposure groups, and approximately 2 for each of the higher exposure groups (30–44, and
≥45 pack-years of smoking), compared with each of the control groups and using never-
smokers as the referent. The spline models, shown in Figure 2, are somewhat more
indicative of a linear relationship—at least until approximately 20 pack-years of smoking—
and this did not change when never-smokers were excluded. Conversely, the p value for
trend for pack-years of smoking was statistically significant only when never-smokers were
included for analysis (Table 3). Lastly, the additional cigarette smoking variables of
duration, intensity, age of initiation, and duration of cessation were not associated with
Barrett’s esophagus, after adjustment for total exposure (Table 3).
As shown in Figure 1, there were moderate-to-high levels of heterogeneity which were
predominantly the product of the relatively lower estimates generated by the FINBAR study.
When the FINBAR study was excluded, the summary ORs from the fully adjusted models
slightly increased and the heterogeneity (I2 values) decreased (Population-based controls:
ORever-smoke=2.09 [95%CI:1.54–2.83, I2=44%]; OR<15=1.93 [95%CI:1.36–2.74, I2=30%];
OR15–29=1.75 [0.93–3.30, 68%]; OR30–44=2.49 [1.70–3.65, 0%]; OR≥45=2.57 [1.79–3.67,
0%]; GERD controls: ORever-smoke=1.75 [95%CI:1.43–2.15, I2=0%]; OR<15=1.32 [0.95–
1.84, 38%]; OR15–29=1.62 [1.09–2.41,25%]; OR30–44=2.87 [1.88–4.38, 19%]; OR≥45=2.12
[1.50–3.00, 0%]).
The stratified models tested whether the effect of a single exposure in relation to Barrett’s
esophagus was modified by another variable. When stratified by sex, the estimates for ever-
smoking and categories of pack-years, in relation to Barrett’s esophagus, were slightly
higher in men (ORever-smoke=1.81 [1.43–2.30, 0%]) than women (ORever-smoke=1.32 [0.91–
1.92, 31%]), compared with GERD controls (Supplementary Table 1). Although ever-
smoking stratified by sex was statistically significant (p=0.041), pack-years of cigarette
smoking was not (p=0.5). Estimates of risk were not statistically different by sex when using
population-based controls as the comparison group. Analyses stratified by BMI indicated
that associations between cigarette smoking and Barrett’s esophagus may be stronger in
those with a lower BMI (p=0.046), when using the population-based controls as the
comparison group, while no pattern by BMI was discernable when compared with GERD
controls (p=0.9; Supplementary Table 2). Analyses stratified by heartburn and regurgitation
provided higher estimates for ever-smoking and pack-years of smoking in relation to
Barrett’s esophagus in individuals without such symptoms (ORever-smoke=3.35 [1.55–7.26,
0%]) compared with individuals who reported symptoms (ORever-smoke=1.99 [1.50–2.65,
23%]) when using population-based controls as the referent, although these differences were
not statistically significant (Supplementary Table 3).
Table 4 shows the results from the interaction models to test departures from additivity,
which are considered as evidence for the existence of biologic interaction. Unlike effect-
measure modification of ORs across strata of a second variable each with an independent
referent group, interaction models simultaneously tested the effects of two exposures in
relation to Barrett’s esophagus to assess whether there were synergistic effects. We found
evidence for biologic interaction between ever-cigarette smoking and heartburn/
regurgitation with an attributable proportion due to interaction amongst those exposed to
both risk factors of 0.39 (95%CI: 0.25–0.52) (Table 4). Compared with the unexposed
referent of population controls without heartburn/regurgitation who also never-smoked, the
ORs for Barrett’s esophagus for each exposure category were 9.35 (95%CI: 6.08–14.39) for
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those exposed to heartburn/regurgitation only, 1.71 (1.04–2.80) for those exposed to
smoking only, and 16.47 (10.73–25.29) for those exposed to both.
Discussion
The relationship between cigarette smoking and Barrett’s esophagus is unclear. Given the
high prevalence of smoking, and its status as one of the few potentially-modifiable risk
factors for Barrett’s esophagus, this relationship requires a more complete understanding. In
this analysis of individual patient data from five studies within the international BEACON
consortium, we found evidence for associations between ever-smoking and increasing pack-
years with increased risk of Barrett’s esophagus. We did not find independent associations
with related exposure variables, such as duration of smoking or the average number of
cigarettes smoked per day, suggesting that the cumulative exposure to cigarette smoke is the
most important exposure in this relationship. We also found tentative evidence that the
relationship between cigarette smoking and Barrett’s esophagus may be stronger in men
which could indicate sex differences in the role of smoking with respect to pathogenesis of
Barrett’s esophagus. Lastly, evidence for biological interaction between heartburn/
regurgitation and cigarette smoking suggests varied mechanistic effects of cigarette smoking
in the development of Barrett’s esophagus.
Our understanding of the relationship between cigarette smoking and Barrett’s esophagus
has been hampered by inconsistent data from studies too small to fully assess the issue;
some studies have found evidence for an association, using population-based controls 23, 24,
endoscopy-negative controls 18, 25, or GERD controls 18, 28–30, while other studies have not
found evidence for a relationship 47–50. The analysis presented herein is much larger than
any of these previous studies, and this larger sample size provided for greater statistical
power and greater precision of risk estimates. In addition, the availability of GERD controls
and population-based controls allowed for comparison to the source population undergoing
endoscopy and the general population, respectively, with the latter also enabling assessment
of heartburn/regurgitation as a potential effect-measure modifier and as a potential
synergistic risk factor. A particular strength of the study is its use of pooled individual
patient data through a large international consortium; this method provides more comparable
statistical estimates than standard meta-analysis, which pool published odds ratios that differ
in their variable definitions and the confounders included. Therefore, the results of this
analysis are the strongest available data to date regarding cigarette smoking as a risk factor
for Barrett’s esophagus.
Barrett’s esophagus is the recognized precursor lesion of esophageal adenocarcinoma, and,
if cigarette smoking was a risk factor for Barrett’s esophagus, one might expect to observe
an association between smoking and esophageal adenocarcinoma as well. Indeed, studies of
this malignancy compared with population-based or hospital controls also provide evidence
for an association with cigarette smoking 50–55 including a recent pooled esophageal
adenocarcinoma analysis from the international BEACON group 22. Given the concordance
of these data, associations between cigarette smoking and Barrett’s esophagus, as well as
cigarette smoking and esophageal adenocarcinoma, are likely to be real and, given the high
prevalence of the exposure, may account for a large proportion (~40%) of esophageal
adenocarcinomas 56. It has not been known where smoking acts in the biological pathway.
The current data suggest that smoking is associated with the risk of an early cancer
precursor: Barrett’s esophagus.
Most of our primary exposure analyses had moderate to high levels of heterogeneity, an
effect predominantly caused by the lower estimates of association from the FINBAR
study 33. Omission of this study reduced the heterogeneity and had minimal effects on the
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summary risk estimates attained, thus reinforcing the conclusions drawn. It is unknown why
the associations between smoking and Barrett’s esophagus were lower in the Irish study
population; the proportion of population-based controls that reported ever-smoking was
higher (55%) than the other studies (45–47%), but this slightly higher rate is insufficient to
mask the association evidenced in the other studies. In addition, the distribution of pack-
years of cigarette smoking was similar across control groups and studies while provision of
individual patient data enabled similar confounding structures to be constructed for study-
specific models. FINBAR’s inclusion criteria did restrict recruitment of cases to those with
long-segment Barrett’s esophagus (≥3 cm, Table 1); a criterion not employed by the other
four studies included in this analysis. However, this is unlikely to have led to lower
estimates of association given that a previous analysis of KPNC data evidenced a stronger
association of cigarette smoking with long-segment Barrett’s esophagus (OR=1.72, 95%CI:
1.12, 2.63) compared with that for short-segment Barrett’s esophagus (<3cm, OR=1.19,
95%CI:0.76, 1.85) 31. Thus, it remains unexplained why the FINBAR estimates of
association were lower relative to the other studies included in this pooled analysis.
Analyses stratified by sex suggested that cigarette smoking may be a stronger risk factor for
Barrett’s esophagus among men than among women. However, this relationship was only
observed when assessing ever-cigarette smoking in Barrett’s esophagus cases compared
with GERD controls; analyses of pack-years of cigarette smoking, and comparisons with
population-based controls were null. Given the known genotoxic effects of tobacco smoke,
evidence that effects of cigarette smoking are similar in men and women 57, and the number
of tests conducted, we believe this result represents a chance finding.
Interaction analyses indicated that heartburn/regurgitation symptoms and ever-smoking
biologically interact in the risk of Barrett’s esophagus—the attributable proportion of
disease amongst individuals exposed to these two factors was estimated to be 0.39 (95%CI:
0.25–0.52). Biological interaction of these variables in this setting is plausible, given
evidence that tobacco smoke may not only have direct genotoxic effects 58 but may also
induce transient lower esophageal sphincter relaxations (TLESRs) 5960, 61, increasing the
likelihood, length and severity of gastroesophageal reflux—a major risk factor for Barrett’s
esophagus 18 and the sequela, esophageal adenocarcinoma 17. Indeed, interaction between
gastroesophageal reflux symptoms and smoking has been previously reported for Barrett’s
esophagus with dysplasia 26 and for esophageal adenocarcinoma 62.
There were several strengths of this analysis. First, the consortial approach enabled
generation of the largest reported cohort of subjects with Barrett’s esophagus in the world’s
literature upon which risk factor analysis has been performed. The large size of the pooled
database enabled more precise estimates of association over previous studies, particularly in
stratified analyses, spline models, and assessment of interaction. Second, although pooling
and harmonization of data is a substantial undertaking and requires expertise, time, and
resources, individual patient data allows for many benefits over meta-analysis of published
estimates including building consistent models across studies, studying novel questions
including interaction and using novel methods of analysis such as splines. Third, the
availability of two control groups for comparison: population-based and GERD allows us to
postulate where risk factors may be active in the pathogenesis of Barrett’s esophagus. This is
important given that it is feasible that a significant proportion of the population-based
control group may unknowingly have Barrett’s esophagus 63, although such
misclassification would bias results toward the null.
Limitations of this analysis include the moderate-to-high levels of heterogeneity for some
analyses. Although constituents of tobacco smoke have changed over time 64, the studies
included in this analysis recruited incident cases and controls over a similar period (1997–
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2006). Regardless, constituents of tobacco smoke are likely to have differed geographically
as is population susceptibility to genotoxic exposures. The unexplained heterogeneity does
warrant a cautious interpretation of summary estimates, although associations were largely
consistent in a majority of studies included and similar summary estimates with low
heterogeneity were estimated when the study which was the source of the most
heterogeneity was omitted from analysis. Another limitation is the possibility of recall bias,
given the case-control design of the included studies, although the intensity and duration of
smoking are usually recalled relatively reliably 65. Lastly, we did not adjust for dietary
variables in this analysis; although previous studies suggest that diet has minimal effects on
relationships between smoking and Barrett’s esophagus, there remains the possibility of
residual confounding through diet and other exposures.
In conclusion, cigarette smoking is a risk factor for Barrett’s esophagus, with adjusted odds
ratios for multiple measures of association in the 1.5–2 range. The association appears to
strengthen with increased exposure to cigarette smoking until approximately 20 pack-years,
where it begins to plateau. If smoking is a causative agent of Barrett’s esophagus, it is an
attractive modifiable risk factor, especially in high risk groups, such as elderly, obese males
with GERD symptoms. Moreover, because the origins of BE are poorly understood, a better
understanding of its risk factors and their biological interactions may allow inference as to
the biological mechanisms involved in the nascent stages of Barrett’s esophagus. Indeed, the
evidence we present for a biological interaction between smoking and heartburn/
regurgitation suggest that cigarette smoking has multifaceted effects in the development of
this precancerous metaplasia.
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Forest plots of the relationship between increasing categories of cigarette smoking and
Barrett’s esophagus compared with (A) population- based controls; and (B)
gastroesophageal reflux (GERD) controls. Each study’s estimate is represented by the
corresponding black square with the arms representing 95 percent confidence intervals. The
grey-box overlaying each estimate represents the weight which it contributes to the pooled
estimate. The pooled estimates are designated by the diamonds which follow each subgroup;
the widths of the diamonds represent the 95 percent confidence intervals.
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Spline plots of the relationship between increasing categories of cigarette smoking and
Barrett’s esophagus compared with (A) population-based controls; and (B) gastroesophageal
reflux (GERD) controls. The solid line represents the estimate of the odds ratio while the
broken lines either side represent 95 percent confidence intervals.
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